InsidersTradesSigma
SC
Strata Critical Medical, Inc. Stock: price and insider trades · United States · SEC (Form 4)
Track the Strata Critical Medical, Inc. stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Strata Critical Medical, Inc. has published 38 insider filings. Market capitalisation: €443.9m. The latest transaction was disclosed on 10 June 2026 (Cession). Among the most active insiders: Cohen Amir. The full history is accessible without an account.
38
Insider Decl.
0
Thresholds
€84,068
2 ops.
Buy Volume
€410,591
6 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Strata Critical Medical, Inc. Strong Buy (bullish), based on 4 analysts. Average price target: US$9.25.
57Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 15,099 of 26,176 companies
47.4
score / 100
Value50
Quality45
FCF yld-14%
Earn yld9.3%
EV/EBITDA·
ROE-6.4%
Gross mgn21%
Net mgn21%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 10 June 2026
Declarations38 total
4,655 sharesClass A common stock, $0.0001 par value per shareSEC:0001628280-26-042182:0
10,300 shares@ US$5.790.0094% mcap11.7% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-038171:0
40,575 shares@ US$5.910.038% mcap47.0% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-038171:1
14,306 shares@ US$5.790.017% mcap38.7% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-034586:0
83,505 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-027658:0
40,960 shares@ US$4.920.042% mcap28.2% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-027658:1
545,625 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-027654:0
301,731 shares@ US$4.920.31% mcap90.7% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-027654:1
630,264 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-027656:0
321,750 shares@ US$4.920.33% mcap100.0% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-027656:1
57,172 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-027661:0
13,922 shares@ US$4.920.014% mcap100.0% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-027661:1
5,483 shares@ US$4.370.0049% mcap11.3% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-26-020490:0
18,067 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-26-019391:0
34,018 shares@ US$4.38Class A common stock, $0.0001 par value per shareSEC:0001628280-25-056756:0
35,348 shares@ US$4.38Class A common stock, $0.0001 par value per shareSEC:0001628280-25-056755:0
21,643 shares@ US$4.38Class A common stock, $0.0001 par value per shareSEC:0001628280-25-056754:0
3,716 shares@ US$4.38Class A common stock, $0.0001 par value per shareSEC:0001628280-25-056752:0
17,000 shares@ US$4.47320.016% mcap50.0% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-25-056310:0
Ideal exit: 5 Sept 2026 (T+270)
5,000 shares@ US$4.365100.0% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-25-055610:0
Ideal exit: 1 Sept 2026 (T+270)
13,395 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-25-055372:0
63,918 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-25-055371:0
20,076 shares0Class A common stock, $0.0001 par value per shareSEC:0001628280-25-055370:0
11,000 shares@ US$4.3750.4% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-25-053810:0
11,000 shares@ US$4.312249.6% of flowClass A common stock, $0.0001 par value per shareSEC:0001628280-25-053386:0
25 of 38 declarations
About Strata Critical Medical, Inc.
Strata Critical Medical, Inc. (NASDAQ: SRTA) is a United States-based, New York-headquartered company focused on time-critical logistics and medical services for the U.S. healthcare market. The company, formerly known as Blade Air Mobility, Inc., underwent a major strategic reset in 2025 after divesting its legacy passenger transportation business. Following that transaction, Strata emerged as a more focused, contract-driven “pure play” medical logistics and clinical services platform, with a business model that is less exposed to consumer travel demand and more anchored to healthcare infrastructure. Strata’s core offering is built around integrated solutions for transplant hospitals and organ procurement organizations. The company provides an end-to-end “one call” solution that can include air and ground logistics, organ placement, surgical organ recovery, normothermic regional perfusion, preservation services, and related coordination support. These capabilities are delivered primarily through the Trinity Medical Solutions and Keystone Perfusion Services brands. In addition, Strata offers perfusion staffing and equipment solutions for cardiovascular surgery centers, broadening its addressable market beyond transplant-related procedures. From a competitive standpoint, Strata operates in a specialized niche, but one with favorable structural dynamics. Demand is supported by the persistent shortage of donor organs, the operational complexity of transplant logistics, and the need to reduce time-sensitive delays across the care pathway. The company’s main differentiator is its integrated service model, which combines transportation, clinical coordination, and procedure execution within a single platform. Management has described Strata as operating one of the nation’s largest air transport and surgical services networks for transplant hospitals and organ procurement organizations in the United States, which suggests a meaningful network position in a highly specialized segment. Geographically, the business is primarily domestic and centered on the United States, where Strata also maintains its principal executive offices in New York. The company is not positioned as a broad international operator; instead, its strategy appears focused on deepening its U.S. footprint and expanding within adjacent medical-critical workflows. Recent corporate milestones have been important for equity investors. In August 2025, Strata completed the sale of its Passenger business to Joby Aviation, formally closed the strategic transition, and began trading under the new ticker SRTA on NASDAQ. In September 2025, the company completed the acquisition of Keystone Perfusion Services, strengthening its capabilities in organ recovery, normothermic regional perfusion, and perfusion-related medical services. More recently, the company reported strong 2025 operating momentum in its 2026 disclosures, including revenue growth and improved guidance, which points to a more streamlined business profile and a clearer earnings narrative centered on critical healthcare services.
